Journal of Acquired Immune Deficiency Syndromes
-
Publication Venue For
-
Brief Report: Relationship Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in Persons With HIV.
84:400-404.
2020
-
The Influence of Social Networks on Antiretroviral Therapy Initiation Among HIV-Infected Antiretroviral Therapy-Naive Youth in Rural Kenya and Uganda..
83:9-15.
2020
-
Brief Report: Diagnostic Accuracy of Oral Mucosal Transudate Tests Compared with Blood-Based Rapid Tests for HIV Among Children Aged 18 Months to 18 Years in Kenya and Zimbabwe..
82:368-372.
2019
-
Discrimination, Medical Distrust, Stigma, Depressive Symptoms, Antiretroviral Medication Adherence, Engagement in Care, and Quality of Life Among Women Living With HIV in North Carolina: A Mediated Structural Equation Model..
81:328-335.
2019
-
Acute HIV Infection and CD4/CD8 Ratio Normalization After Antiretroviral Therapy Initiation..
79:510-518.
2018
-
Integrated Treatment for Smoking Cessation, Anxiety, and Depressed Mood in People Living With HIV: A Randomized Controlled Trial..
79:261-268.
2018
-
Retention in HIV Care During Pregnancy and the Postpartum Period in the Option B+ Era: Systematic Review and Meta-Analysis of Studies in Africa..
77:427-438.
2018
-
Brief Report.
72:184-188.
2016
-
Association Between Missed Early Visits and Mortality Among Patients of China National Free Antiretroviral Treatment Cohort.
60:59-67.
2012
-
116 Autologous and Heterologous Neutralizing Antibody Responses in HIV-1 Infection.
59:47-47.
2012
-
The differential binding and activity of PRO 2000 against diverse HIV-1 envelopes..
51:125-129.
2009
-
Effect of trimethoprim-sulfamethoxazole prophylaxis on antimicrobial resistance of fecal Escherichia coli in HIV-infected patients in Tanzania..
47:585-591.
2008
-
False-positivity of HIV-2 immunoblots in a cohort of elite suppressors infected with HIV-1..
47:644.
2008
-
Utilization of mental health and substance abuse care for people living with HIV/AIDS, chronic mental illness, and substance abuse disorders..
47:449-458.
2008
-
The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy..
47:194-201.
2008
-
Inclusion of adolescents in preventive HIV vaccine trials: public health policy and research design at a crossroads..
47:86-92.
2008
-
Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120..
46:222-230.
2007
-
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial..
44:203-212.
2007
-
Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy..
44:159-166.
2007
-
An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains..
43:270-277.
2006
-
Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine..
43:284-292.
2006
-
Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States..
42:298-306.
2006
-
HIV-1 infection initiates an inflammatory cascade in human renal tubular epithelial cells..
42:1-11.
2006
-
Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview..
41:323-331.
2006
-
Increased circulating interleukin-7 levels in HIV-1-infected women..
40:581-584.
2005
-
Validation of a brief screening instrument for substance abuse and mental illness in HIV-positive patients..
40:434-444.
2005
-
Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV..
38:124-134.
2005
-
Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation..
37:1581-1583.
2004
-
Portable colposcopy in low-resource settings..
37 Suppl 3:S167-S170.
2004
-
The impact of race/ethnicity on mother-to-child HIV transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316..
36:800-807.
2004
-
Prevalence of chemokine and chemokine receptor polymorphisms in seroprevalent children with symptomatic HIV-1 infection in the United States..
35:309-313.
2004
-
Changes in CD4+ T-cell differentiation phenotype during structured treatment interruption in patients with chronic HIV-1 infection..
34:475-481.
2003
-
Contraception use, family planning, and unprotected sex: few differences among HIV-infected and uninfected postpartum women in four US states..
33:608-613.
2003
-
Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose..
33:153-156.
2003
-
Adherence to antiretroviral therapy among patients with HIV: a critical link between behavioral and biomedical sciences..
31 Suppl 3:S98-102.
2002
-
Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A..
29:254-261.
2002
-
Addressing the challenges of adherence..
29 Suppl 1:S2-10.
2002
-
Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000..
29:184-190.
2002
-
Who will enroll? Predicting participation in a phase II AIDS vaccine trial..
27:281-288.
2001
-
Rationing HIV medications: what do patients and the public think about allocation policies?.
26:56-62.
2001
-
Early detection: the next steps..
25 Suppl 2:S157-S159.
2000
-
Seroprevalence of HTLV-I in Cheju Island, a Korean island adjacent to the endemic area of Japan..
22:409-412.
1999
-
Authors’ reply: To the editor.
6:1175.
1993
-
B-101 Placental exosomes in maternal-placental-fetal communication and viral resistance
2019
-
A-102 Antibody binding to HIV-1 infected cells as mechanism for treatment of HIV infection
2018
-
D-107 Vaccination establishes CXCR5+PD1+CD4+ peripheral blood germinal center T follicular helper cell relatives in humans
2016
-
E-103 The pathway to HIV vaccine development
2016
-
A-112 DNA and Protein Co-immunization Improves the Magnitude, Longevity, and mucosal dissemination of Immune Responses
2014
-
E-102 Advances in Prophylactic HIV Vaccine Development
2014
-
Analysis of Broad Neutralizing B Cell Lineages to Guide HIV-1 Immunogen Design
2013
-
Comparison of systemic and mucosal responses after DNA and protein co-immunization
2013
-
HIV-1 Vaccine Elicited IgA and IgG Antibody Specificities
2013
-
Identification of Three Distinct Epitope Regions in the V2 Portion of gp120
2013
-
Magnitude, Breadth and Duration of HIV-1 Vaccine-Elicited Neutralizing Antibody Responses
2013
-
114 Role of Vaccine-induced V2 Antibodies in Protection From HIV Infection of Recipients in the RV144 Clinical Vaccine Trial
2012
-
142 HIV Frequently Elicits Mucosal and Plasma Env-Specific IgA With a Rapid Initial Decline In Acute Infection
2009